• Alda 1 Workflows for ALDH2 Cardiac Research

  2026-09-01

  Alda 1 is a genotype-aware ALDH2 activator for connecting aldehyde handling with cardiomyocyte proliferation, pressure-overload heart failure, and cardiac ischemia research. This workflow-focused guide covers assay design, exploratory dosing, variant comparisons, and troubleshooting, while separating mechanistic evidence from translational hypotheses.

• Palonosetron Hydrochloride: Receptor-to-Kidney Insight

  2026-08-31

  Palonosetron hydrochloride is more than a long-acting 5-HT3 receptor antagonist: it is a useful probe for connecting receptor pharmacology with renal organic-cation transport. This article translates receptor and OCT2/MATE1 assay evidence into practical decisions for cancer research and antiemetic studies.

• THZ1 for Reliable CDK7 Cell Assays

  2026-08-31

  Learn how THZ1 (SKU A8882), a covalent CDK7 inhibitor, can improve the interpretation and reproducibility of cell viability, proliferation, and cytotoxicity workflows. This scenario-based guide connects mechanism, solvent handling, concentration design, orthogonal apoptosis assays, and practical supplier evaluation for cancer biology and T-ALL research.

• ER Stress, GRP78/ATF6/CHOP, and Intestinal Stem Cells

  2026-08-30

  The reference study identifies unresolved endoplasmic reticulum stress as a negative regulator of intestinal stem-cell abundance and differentiation in mice. Its central contribution is the mechanistic connection of GRP78/ATF6/CHOP activation and p44/42 MAPK suppression with crypt-cell apoptosis, reduced proliferation, and intestinal barrier injury.

• Proteoform-Specific Drug Interactions in Native Membranes

  2026-08-29

  Lutomski and colleagues developed a native mass-spectrometry workflow that releases membrane proteins and signaling complexes directly from retina rod disc membranes, preserving links between proteoforms, lipid modifications, and binding partners. The study shows how this approach can distinguish off-target interactions of sildenafil and vardenafil with PDE6 and reveal modification-dependent assembly of G-protein complexes.

• LGK-974 Workflow for Wnt-Driven Cancer Studies

  2026-08-29

  Build reproducible PORCN inhibition workflows for Wnt secretion, pathway-response, and pancreatic cancer assays with LGK-974. The guide connects upstream Wnt ligand control to the CDK4/6–BET findings reported in PDAC and highlights practical dosing, controls, and troubleshooting.

• Methylprednisolone Sodium Succinate: Research Guide

  2026-08-28

  Methylprednisolone Sodium Succinate is a synthetic corticosteroid for controlled inflammation, immunology, and cell-response studies. Product specifications, concentration-dependent leukocyte findings, and historical acute spinal cord injury data support mechanistic research, but they do not establish a universal clinical treatment protocol.

• Digoxin Beyond Ion Transport: HIF-1α in TED

  2026-08-28

  Digoxin is more than a Na+/K+ ATPase pump inhibitor: new research connects it to HIF-1α-driven inflammation and fibrosis in thyroid eye disease. This article translates that finding into practical assay design while distinguishing cardiac, TED, and antiviral evidence.

• SU6656: A Mechanistic Guide for Platelet Models

  2026-08-27

  SU6656 Src tyrosine kinases inhibitor research spans megakaryocyte polyploidization and vascular responses to radiation. This article clarifies what the 2026 hiPSC platelet study directly demonstrates, where SU6656 remains a testable intervention, and how to design informative assays without overextending the evidence.

• Angiotensin I/II (1-5) Protocol Guide

  2026-08-27

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for controlled renin-angiotensin system research involving cardiovascular, renal, blood pressure, or aldosterone-related endpoints. It is not a general-purpose signaling reagent and requires solvent planning because it is insoluble in water.

• Adefovir Pharmacokinetics in OAT1 Cocktails

  2026-08-26

  The 2024 reference study uses population pharmacokinetic modeling to explain why adefovir exposure increased modestly in a transporter cocktail without evidence of altered renal elimination. Its analysis separates apparent absorption and prodrug-conversion effects from OAT1-mediated clearance, strengthening the interpretation of adefovir as a renal transporter probe.

• EGF Drives A549 Migration Without EMT or Invasion

  2026-08-26

  The reference study separates epidermal growth factor-driven migration from epithelial–mesenchymal transition and extracellular-matrix invasion in A549 lung adenocarcinoma cells. Its combined imaging, pathway, transcript, protein, and proteomic analyses show that EGF promotes migration through MAPK-dependent signaling, whereas TGFβ more strongly controls EMT-associated invasion.

• Sulfachloropyridazine Research Workflows

  2026-08-25

  Sulfachloropyridazine connects DHPS biochemistry with antimicrobial susceptibility testing, microbiome profiling, and infection-model research. This workflow shows how to control solubility, separate direct enzyme inhibition from ecological effects, and use paired 16S rRNA and metabolomics readouts for more interpretable results.

• WP1066: JAK2/STAT3 Inhibitor Workflows

  2026-08-25

  Build reproducible WP1066 experiments for JAK2/STAT3 pathway validation, cancer cell proliferation assays, and apoptosis profiling. The same inhibitor can also serve as a mechanistic perturbation tool when evaluating macrophage signaling in regenerative biomaterials, provided pathway inhibition is separated from pathway-activation experiments.

• Senescent CAFs Suppress NK Immunity in Breast Cancer

  2026-08-24

  Ye et al. identify a senescent myofibroblast cancer-associated fibroblast population that promotes breast cancer progression by producing extracellular matrix that restrains natural killer cell cytotoxicity. Genetic or pharmacologic elimination of these senCAFs restored antitumor immune activity in mice, while their presence in human breast lesions was associated with recurrence risk, supporting stromal targeting as a mechanistically grounded therapeutic strategy.

451 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page